The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Spectrum Pharmaceuticals Inc

Nasdaq: SPPI
Last

(U.S.) $6.61

Today's change+0.06 +0.99%
Updated March 24 4:00 PM EDT. Delayed by at least 15 minutes.
 

Spectrum Pharmaceuticals Inc

Nasdaq: SPPI
Last

(U.S.) $6.61

Today's change+0.06 +0.99%
Updated March 24 4:00 PM EDT. Delayed by at least 15 minutes.

Spectrum Pharmaceuticals Inc up (U.S.)$0.07

Spectrum Pharmaceuticals Inc closed up Friday by (U.S.)$0.07 or 0.99% to (U.S.)$6.61. Over the last five days, shares have gained 0.61% and 49.21% year to date. Shares have underperformed the S&P 500 by 4.22% during the last year.

Key company metrics

  • Open(U.S.) $6.55
  • Previous close(U.S.) $6.55
  • High(U.S.) $6.68
  • Low(U.S.) $6.54
  • Bid / Ask-- / --
  • YTD % change+49.21%
  • Volume521,322
  • Average volume (10-day)1,118,791
  • Average volume (1-month)962,552
  • Average volume (3-month)763,259
  • 52-week range(U.S.) $3.21 to (U.S.) $7.74
  • Beta1.46
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.93
Updated March 24 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-46.78%

Although this company's net profit margin is negative, it is above the industry average and implies that Spectrum Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.06%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue35333444
Total other revenue--------
Total revenue35333444
Gross profit24242637
Total cost of revenue111087
Total operating expense53495650
Selling / general / administrative18192822
Research & development16131415
Depreciation / amortization7766
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-17-16-22-6
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-19-18-24-9
Income after tax-17-17-24-9
Income tax, total-2000
Net income-17-17-24-9
Total adjustments to net income--------
Net income before extra. items-17-17-24-9
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-17-17-24-9
Inc. avail. to common incl. extra. items-17-17-24-9
Diluted net income-17-17-24-9
Dilution adjustment--------
Diluted weighted average shares80796966
Diluted EPS excluding extraordinary itemsvalue per share-0.22-0.22-0.35-0.14
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.22-0.22-0.35-0.14